Journals / Klinik Psikofarmakoloji Bülteni / 2003 / Cilt: 13 - Sayı: 3

Case report: A mixt episode incuded by sibutramine

Sibutramin ile indüklenen bir mikst epizot olgusu

Pages
129–132
Publication Date
2022-10-17
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Since sibutramine has an antidepressant activity drug which may cause affective or psychotic symptoms we wanted to highlight the importance of evaluating the mental and psychiatric status of patients during and prior to treatment.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Sibutramine is an antiobesity drug which has also an inbitor effect on NE and 5HT reuptake pumps.
📊
Key Findings & Data:Here, we want to report a 53 years old male patient who did not have any prior hypomanic or manic episodes had a mixed episode after a 3 months of antiobesity treatment by 30 mg/day sibutramine.
💡
Conclusion & Impact:Since sibutramine has an antidepressant activity drug which may cause affective or psychotic symptoms we wanted to highlight the importance of evaluating the mental and psychiatric status of patients during and prior to treatment.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Sibutramine is an antiobesity drug which has also an inbitor effect on NE and 5HT reuptake pumps. These antidepressant pharmacodynamic properties of sibutramine has been proved by pre-clinical and clinical trials. Here, we want to report a 53 years old male patient who did not have any prior hypomanic or manic episodes had a mixed episode after a 3 months of antiobesity treatment by 30 mg/day sibutramine. Since sibutramine has an antidepressant activity drug which may cause affective or psychotic symptoms we wanted to highlight the importance of evaluating the mental and psychiatric status of patients during and prior to treatment.

Özet

Sibutramin, NE ve 5HT geri alım pompa inhibitörü özelliği olan ve obezite tedavisinde kullanılan bir ilaçtır. Antidepresan özellikteki farmakodinamik etkileri pre-klinik ve klinik çalışmalarla kanıtlanmıştır. Bu yazıda önceden bir manik ya da hipomanik epizod yaşamamış, obezite tedavisi amacıyla 3 ay süreyle 30 mg/ gün dozda sibutramin kullanımı sonrasında mikst epizod ortaya çıkmış 53 yaşındaki bir erkek olgudan söz edilmektedir. Antidepresan etkisi bilinen sibutramin, duygudurum bozuklukluğu ya da psikotik belirtilere neden olabileceğinden sağaltım öncesinde ve sağaltım sürecinde kişinin mental durumunun ve psikiyatrik durumunun değerlendirilmesinin önemi vurgulanmıştır.

🔖

Cite This Article

PIRILDAR, Ş., ÖZAŞKINLI, S., EKER, M. Ç., ONAT, Ö. (2022). Case report: A mixt episode incuded by sibutramine. Klinik Psikofarmakoloji Bülteni, Cilt: 13 - Sayı: 3, 129–132. https://ajindex.com/articles/574481

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (2)

  1. Brownel KD, Wadden TA Sadock. Psychological Factors Affecting Medical Conditions: Obesity Chapter 25-1
  2. Sadock B J, Sadock V A, (editors); Kaplan and Sadock’s Comprehensive Textbook of Psychiatry. 7th ed. on CD-ROM. East Washington Square: Lippincott Williams and Wilkins 2000 2.Bray GA. A concise review on the therapeutics of obesity. Nutrition 2000;16:953-60 3.Proietto J, Fam BC, Ainslie DA, Thornburn AW. Novel anti-obesity drugs. Expert Opin Investing Drugs 2000;9:1317-26 4.Buckett WR, Thomas PC, Luscombe GP Th pharmacology of sibutramine hydrochloride (BTS 54 524), a new antidepressant which induces rapid noradrenerjic down-regulation. Prog Neuropsychopharmacol Biol Psychiatry 1988;12:575-84 5.Heal DJ, Prow MR, Buckett WR Effects of antidepressant drugs and electroconvulsive shock on pre- and postsynaptic alpha 2- adrenoceptor function in the brain: rapid down regulation by sibutramine HCl; Psychopharmacology 1991;103:251-7 6. Luscombe GP, Hopcroft RH,.thomas PC, Buckett WR The contribution of metabolytes to the rapid and potent down regulation of rat cortical beta-adrenoceptors by the putative antidepressant sibutramine hydrochloride. Neuropharmacology 1989;28:129-34 7.Luscombe GP, Slater NA, Lyons MB, Wynne RD, Scheinbaum ML, Buckett WR Effect on radiolabelled-monoamine uptake in vitro of plasma taken from healthy volunteers administered the antidepressant sibutramine HCl. Psychopharmacol 1990;100:345-9 8.Heal DJ, Prow, MR, Gosden J, Luscombe GP, Buckett WR A comparison of various antidepressant drugs demonstrates rapid desensitisation of alpha 2-adrenoceptors exclusively by sibutramine hydrochloride. Psychopharmacology 1992;107:497-502 9.T aflinski T,Chojnacka J Letter to the editor: Sibutramine associated psychotic epizode. Am J Psychiatry. 2000;157:2057-8 10.Benazzi F Ogranic hypomania secondary to sibutramine -citalopram interaction. Letter to the editor. J Clin Psychiatry 2002;63:2:165 11.Cordeiro Q, Vallada H Sibutramine-induced mania episode in a bipolar patient. Letter to the editor. Int J Neuropsychopharmacol. 2002;5:283-284 12.Shulman RB, Scheftner WA, Nayudu S Venlafaxine associated mania. Letter to editors. J Clin Psychopharmacol 2001 Apr;21:239-41 13.Post RM, Altshuler LL, Frye MA Rate of switch in bipolar patients prospectively treated with second-generation antidepressants as augmentation to mood stabilizers. Bipolar Disorders 2001;3:259-265